Human Pheromone Sciences, Inc. (NASD: EROX) (“the Company”) confirmed today that an independent study conducted by researchers at the University of California, Berkeley, and recently published in the scientific journal, Psychoneuroendocrinology, involved 4,1 6-androstadien-3-one (androstadienone), one of the primary compounds used in the Company’s patented technology.
The study, performed by members of the Helen Wills Neuroscience Institute and the Department of Psychology at the University, measured in 60 subjects the effects of just sniffing various concentrations of the compound on autonomic nervous system function and mood. Simply stated, higher concentrations of this compound increased positive mood and decreased negative mood in the women tested. Psychological and physiological evaluation methods were used to measure the effects on the women in the study.
In commenting on this new research, a Company spokesperson indicated that this new data, issued by a prestigious group of independent scientists, once again validates the studies performed by the Company’s scientists and other independent research projects
performed at leading research centers around the world, including Stanford University, the University of Chicago and the Karolinska Institute in Sweden.
Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the REALM®, innerREALM®, EROX® and Natural Attraction® trademarks. These products contain synthesized human pheromones covered under U.S. and foreign patents. Scientific and consumer studies have shown that the Company’s human pheromones positively impact on the moods, attitudes and emotions of wearers.